<DOC>
	<DOCNO>NCT02883439</DOCNO>
	<brief_summary>The aim study investigate compare bioavailability MP29-02 fluticasone propionate nasal tissue nasal application . This may provide rational basis use 1 puff per nostril dosage regimen drug . Clinical experience demonstrate efficacy twice-daily treatment ; however , far , data available local tissue concentration MP29-02 topical application .</brief_summary>
	<brief_title>Open Label Two -Treatment Half Side Comparative Study Analyse Difference Bioavailability Between MP29-02 Fluticasoen Propionate</brief_title>
	<detailed_description>The study single-centre , two-treatment half-side comparative open-label trial ; subject receive DymistaÂ® Flixonase Aqua one nostril . Nasal tissue sample obtain 24 patient . Subjects select base subject plan undergo septoplasty , septorhinoplasty , functional endoscopic sinus surgery . Subjects different diagnosis add study : non-allergic rhinitis , allergic rhinits , chronic sinusitis nasal polyposis . The number subject base previous experiment presence fluticasone propionate test human nasal mucosal surface human nasal tissue nasal application ( Bonsmann , 2001 ) .</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male female patient Age : 18 70 year ( include ) Subjects need undergo septoplasty , septorhinoplasty functional endoscopic sinus surgery unrelated study Willing able provide inform consent Patients member staff relatives thereof directly involved conduct protocol Participant trial last 30 day Previous treatment Dymista topical corticosteroid spray drop within last month operation Previous treatment systemic corticosteroid last 2 month operation Previous treatment antihistaminics 7 day operation Pregnant breast feed woman Allergic one compound azelastinehydrochloride fluticasonpropionate Significant comorbidity ( instance , limit ) : Glaucoma , cataracts , increase intraocular pressure . Subjects active quiescent tuberculosis ; fungal , bacterial , viral , parasitic infection ; ocular herpes simplex Subjects severe liver disease Use prohibit concomitant medication Potent inhibitor cytochrome P450 ( CYP ) 3A4 Ritonavir Patients unwilling unable attend propose visit schedule Patients suspect know trustworthy likely comply study directive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MP29-02</keyword>
</DOC>